Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TYR | P14679 | 2/20 | 0.54 |
| ▸ | TACR1 | P25103 | 2/20 | 0.52 |
| ▸ | CTSL | P07711 | 5/20 | 0.52 |
| ▸ | CTSB | P07858 | 4/20 | 0.52 |
| ▸ | CTSS | P25774 | 4/20 | 0.52 |
| ▸ | CTSK | P43235 | 1/20 | 0.51 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9744847 | 0.96 | TYR (0.58) | TYRTACR1CTSLCTSBCTSS | |
| SCHEMBL25471796 | 0.92 | TYR (0.54) | TYRTACR1CTSLCTSBCTSS | |
| SCHEMBL29774427 | 0.92 | TYR (0.54) | TYRTACR1CTSLCTSBCTSS | |
| SCHEMBL25471896 | 0.91 | TYR (0.52) | TYRTACR1CTSLCTSBCTSS | |
| SCHEMBL25471793 | 0.91 | TYR (0.56) | TYRTACR1CTSLCTSBCTSS | |
| SCHEMBL27406814 | 0.91 | TYR (0.56) | TYRTACR1CTSLCTSBCTSS | |
| SCHEMBL25471904 | 0.90 | TACR1 (0.53) | TYRTACR1CTSLCTSBCTSS | |
| SCHEMBL25471801 | 0.90 | TACR1 (0.53) | TYRTACR1CTSLCTSBCTSS | |
| SCHEMBL3642862 | 0.89 | ALDH1A1 (0.55) | TYRTACR1CTSLCTSBCTSS | |
| SCHEMBL3642865 | 0.89 | ALDH1A1 (0.55) | TYRTACR1CTSLCTSBCTSS |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230157985-A1 | METHODS FOR TREATMENT OF PARKINSON'S DISEASE | NEURODERM, LTD. (IL) | 2023-05-25 | — | — | US | disclosed |
| US-20230157985-A1 | METHODS FOR TREATMENT OF PARKINSON'S DISEASE | NEURODERM, LTD. (IL) | 2023-05-25 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230157985-A1 | METHODS FOR TREATMENT OF PARKINSON'S DISEASE | DDC, DDT, COMT | TYR 460/4885TACR1 553/4885CTSL 658/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.